SynthesisHealth technology assessment (Winchester, England)2024
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Steven J Edwards et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this paperpooled itcites it